



Friday Five

November 2, 2018

In this issue...

1. Updates on the Removal of lisdexamfetamine (Vyvanse®), methylphenidate OROS (Concerta®), and methylphenidate MLR (Biphentin®) from the M3P Program
2. Submission from Manitoba Health: Pneumococcal Vaccine
3. Standards of Practice Updates
4. Initiating ORT in your Pharmacy Practice
5. Upcoming Professional Development Opportunities

Updates on the Removal of lisdexamfetamine (Vyvanse®), methylphenidate OROS (Concerta®), and methylphenidate MLR (Biphentin®) from the M3P Program

A notice was sent by the College on Oct. 24th informing all practicing pharmacists and physicians that, effective immediately, the following three long-acting stimulants used to treat attention deficit/hyperactivity disorder were removed from the list of drugs covered by the M3P Program:

1. lisdexamfetamine (Vyvanse®)
2. methylphenidate OROS (Concerta®)
3. methylphenidate MLR (Biphentin®)

This change also applies to the generic equivalents of these drugs in addition to the brand name products. All other stimulants, including mixed amphetamine salts, and methylphenidate IR and SR, remain on the M3P drug list. An updated M3P drug list can be found [here](#).

Professional Development Opportunities

Opioid Replacement Therapy 101 Introduction to Clinical Practice

[November 22 & 23, 2018](#)
[February 28 & March 1, 2019](#)
[\(Dauphin\)](#)
[March 21 & 22, 2019 \(The Pas\)](#)
[April 25 & 26, 2019](#)

Online Programs:

[Ordering Lab Tests for Manitoba Pharmacists](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

[Self-Limiting Conditions Independent Study Program](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

Please note that verbal order prescriptions for these medications are not permitted, but electronic and fax transmission of these prescriptions are acceptable. As well, part fills of these medications are allowed if the prescriber states in writing the total quantity to be dispensed, the quantity of each fill, and the specific time interval. These prescriptions cannot be transferred to another pharmacy.

The [Outline of Prescription Drug Regulations](#) and [Outline of M3P Prescription Drug Regulations](#) charts on the College website have been updated to include a summary of these changes.

The College would like to thank all members who provided feedback on these proposed changes in response to the June 1, 2018 Friday Five article.

Submission from Manitoba Health: Pneumococcal Vaccine

The following information was provided by Manitoba Health, Seniors and Active Living.

As you are seeing clients who are 65 years of age and older for their influenza vaccine, why not see if they also require their pneumococcal vaccine?

As per [Manitoba's Eligibility Criteria for Publicly-funded Vaccines](#), all individuals 65 years of age and older are eligible to receive 1 dose of Pneu-P-23 (Pneu-P-23) vaccine. Manitoba Health, Seniors and Active Living (MHSAL) sends letters to those who have turned 65 years of age in the last year to advise them of their eligibility for the Pneu-P-23 vaccine. **These letters are not required in order for them to be immunized and all seniors 65 years of age and older are eligible for a one (1) lifetime dose (unless they meet the high risk eligibility).** It is advised that a client's immunization record be reviewed to determine eligibility.

Individuals from 2 to 65 years of age with the following high-risk medical conditions are eligible to receive 1 dose of Pneu-P-23:

- Chronic cerebral spinal fluid (CSF) leak
- Cochlear implants (including those children who

All PD opportunities are listed on the College website under

[Upcoming Professional Development Opportunities](#)

- are to receive implants)
- Chronic cardiac or pulmonary disease
 - Diabetes mellitus
 - Chronic kidney disease
 - Chronic liver disease (including hepatic cirrhosis due to any cause)
 - Hemoglobinopathies
 - Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
 - Asplenia (functional or anatomic)
 - Immunocompromising therapy including use of long-term corticosteroids, post-organ transplant therapy, and certain anti-rheumatic drugs
 - HIV infection
 - Hematopoietic stem cell transplant recipient ([as per CancerCare Manitoba Blood and Marrow Transplant \(BMT\) Immunization Schedule](#))
 - Solid organ or islet transplant (candidate or recipient)
 - Chronic neurologic condition that may impair clearance of oral secretions
 - Nephrotic syndrome
 - Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
 1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
 2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)

Additional eligibility criteria around lifestyle factors and re-immunization can be found in [Manitoba's Eligibility Criteria for Publicly-funded Vaccines](#)

Reminder: Any immunization that is being administered by a pharmacist is to be inputted into DPIN and the PS code is entered in order for the dose to be recorded onto the client's immunization record

and for MHSAL to pay the pharmacies accordingly.

Please contact MHSAL at 204-788-6737 should you have any questions.

Standards of Practice Updates

Practice Direction Review Survey

Practice Directions carry similar legal significance to regulations, it is therefore important that the formation of a Practice Direction is made with due diligence, subject to analysis, review and response. In 2014, the College of Pharmacists of Manitoba (College) Council implemented a policy surrounding Practice Directions, which includes the requirement for assessment and regular review at a minimum of every five years. As a large number of Practice Directions (13 in total) received approval and were implemented in 2014, they are now due for their 5-year review.

The Standards of Practice Division of the Quality Assurance Committee is requesting your input and feedback within the review process of these Practice Directions. This includes your participation in a series of short surveys allowing for the collection of your responses and comments specific to the identified practice directions.

This particular survey within the series will be specific for two Practice Directions, focusing on [Adaptation of a Prescription](#) and [Test Interpretation \(patient administered automated tests\)](#). The survey contains eight questions, taking approximately 10 minutes for completion, and will remain open for the next two weeks. Your valuable input is greatly appreciated and will contribute towards the analysis and review of these specific practice directions.

The Practice Direction Review survey link can be found [here](#).

Retirement of Community Standards of Practice

The Community Pharmacy Standards of Practice was originally developed in 2006 and accepted as a Practice Direction by College Council under the new legislation (*The Pharmaceutical Act and Regulations*).

This document was intended to serve as a Practice Direction on an interim basis, allowing the Standards of Practice Division of the Quality Assurance Committee sufficient time to focus on the creation of new Practice Directions that reflected the new regulations and expanded scope of practice for Manitoba pharmacists.

As a result of the continued efforts of the Standards of Practice Division in regards to Practice Direction development, College Council has approved the “retirement” of the Community Pharmacy Standards of Practice document as of October 31st, 2018, with the exception of the section, “Standard #1: Drug Distribution F. International Prescription Service Pharmacy”.

Pharmacists should be aware that all of the relevant content from the Community Pharmacy Standards of Practice has either been incorporated into existing Practice Directions, or new Practice Directions have been created, with the exception of the “Drug Information” section of this document. Council has approved that the “Drug Information” section of this document be further assessed by the Standards of Practice Division in late 2019, with further discussion surrounding the necessity of a Practice Direction on this subject.

The “International Prescription Service Pharmacy” section of this document has been extracted and will continue to remain posted as an accepted interim Practice Direction, until the Distance Care Practice Direction is completed and approved by Council.

Initiating ORT in your pharmacy

The opening of three new [Rapid Access to Addictions Medicine Clinics](#) in several locations in Manitoba and the expansion of Pharmacare coverage of buprenorphine/naloxone provide more patients with the ability to access life-saving treatment for opioid use disorder. In order to provide safe care to patients on opioid replacement therapy (ORT), a pharmacist must first have the requisite knowledge, skill and judgment.

At least one pharmacist within a pharmacy that dispenses methadone or buprenorphine/naloxone must have completed specialized training in ORT. If this is not possible due to patient care demands, a pharmacy may dispense methadone or buprenorphine/naloxone if a pharmacist working at the pharmacy completes the required training within 6 months of initiating care, and works with a trained pharmacist from another pharmacy functioning as a mentor, until the training is completed. The pharmacist with specialized training at a pharmacy is responsible for training all pharmacists who will be dispensing methadone and/or buprenorphine/naloxone.

It is strongly recommended that all pharmacists dispensing methadone and/or buprenorphine/naloxone complete the theoretical training, "[Opioid Replacement Therapy 101: An introduction to clinical practice](#)" program, to gain additional insight on the interprofessional collaborative approach to opioid replacement therapy. More information on the required training for methadone or buprenorphine/naloxone can be found in the [Opioid Replacement Therapy Guidelines for Manitoba Pharmacists](#). The College website also includes links to additional recommended readings and resources on methadone and buprenorphine/naloxone.

Please note that pharmacists who previously completed the Principles for the Provision of Opioid Dependence Treatment by Manitoba Pharmacists certificate program are encouraged to complete the new, updated program, which includes more extensive information on ORT, including buprenorphine/naloxone.

If your pharmacy is interested in or is requested to dispense opioid replacement therapy medications and you have questions on setting up your practice, please review the [Opioid Replacement Therapy Guidelines](#) and contact the College for assistance in determining the education required for you and your staff.

200 Taché Avenue, Winnipeg, MB R2H 1A7

Phone: 204.233.1411

www.cphm.ca

The *Friday Five* e-bulletin is published by the **College of Pharmacists of Manitoba** and is forwarded to every licenced pharmacist and pharmacy owner in the Province of Manitoba. Decisions of the College of Pharmacists of Manitoba regarding all matters such as regulations, drug-related incidents, etc., are published in the *Friday Five* . The College of Pharmacists of Manitoba therefore assumes that all pharmacists and pharmacy owners are aware of these matters.

To download af PDF of this e-newsletter, please click

[Friday Five & Newsletter](#) , on www.cphm.ca .